
Development of innovative immunotherapies against cancer using advanced genetic engineering and artificial intelligence technologies.
A
CSR Analysis score
The organization is among the top 5% of organizations with the most committed CSR positioning, among comparable organizations.
+160,000
Total organizations analyzedAnalysis by axis
Access the detailed report with all sector benchmarks, in-depth competitive analysis and actionable recommendations.
Methodology: Score calculated according to 6 CSR themes (Carbon, Biodiversity, Circular Economy, Sustainable Investments, Governance, Social Impact)
Sources: Public data, CSR reports, documented initiatives, official databases
Last update: January 2026
This analysis is not yet available in English. Please see the French version.
Leading organizations
Priothera
B
Development of innovative therapies for hematological malignancies, focusing on immune modulators to enhance outcomes in allogeneic hematopoietic cell transplantation and CAR T cell therapy.
Cellectis
B
Development of cell and gene therapies using gene editing to treat cancer and other diseases. The company uses its TALEN® technology to create off-the-shelf allogeneic CAR T cells.
MaaT Pharma
A
Development of microbiome therapeutics to improve cancer treatment outcomes through immune modulation.
Initiatives identified among leaders
Gouvernance des conditions de travail et sécurité
“MaaT Pharma met en place une gouvernance des condi...” - MaaT PharmaDéfinition d'un code de conduite éthique
“Définition d'un code de conduite éthique pour les ...” - CellectisBilan carbone global
“Priothera développe des thérapies innovantes pour ...” - Priothera36% of similar organizations communicate on CSR issues
+169 initiatives collected from 50 similar organizations
Is your score incomplete? Update your CSR information and improve your positioning.
Claim this page
Updated data
Personalized recommendations
Access complete data, competitive analyses and actionable recommendations for your clients.
Comprehensive sector benchmarks
Competitive data
Ready-to-use reports